Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05438264 · ClinicalTrials.gov registry record · Early Phase 1
Effect of Donepezil on Speech Recognition in Cochlear Implant Users
A Early Phase 1 study of Bilateral Sensorineural Hearing Loss, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05438264 is a Early Phase 1 study of Bilateral Sensorineural Hearing Loss that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 50 participants, below the 327-participant average among 3 other Bilateral Sensorineural Hearing Loss trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05438264, a Early Phase 1 study of Bilateral Sensorineural Hearing Loss, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Hearing loss is a major cause of disability that affects over 48 million Americans. There are currently no medications used to treat sensorineural hearing loss. Cochlear implants can significantly restore hearing in adults with moderate to profound sensorineural hearing loss, but their utility is limited by the wide variability in hearing outcomes. Differences in cochlear implant outcomes may be explained by neuroplasticity, as neural networks must reorganize to process the new auditory information provided by the implant. The investigators predict that cholinergic enhancement with donepezil (an acetylcholinesterase inhibitor) may facilitate cortical reorganization in cochlear implant users, leading to functional improvements in speech recognition and cognition. In addition to taking donepezil, study participants will be asked to increase their daily processor use. Studies suggest that increasing daily device use can improve speech recognition, and this study will explore whether this effect can be augmented further with donepezil. In this randomized, double-blind controlled trial, the investigators aim to assess the effects of donepezil on speech recognition, cortical plasticity, and cognition. Participants will start daily treatment with either donepezil 5 mg or placebo. Participants will be followed longitudinally at 1 month and 3 months after starting the study. The findings from this study will provide important insight into the mechanisms of hearing restoration and could potentially improve hearing and cognitive outcomes for future cochlear implant users.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Donepezil
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-10 |
| Est. Completion | 2026-09-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05438264
The ClinicalTrials.gov registry entry for NCT05438264 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 3 other Bilateral Sensorineural Hearing Loss trials with a reported enrollment target (85% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bilateral Sensorineural Hearing Loss appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05438264 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05438264 about?
NCT05438264 is a clinical study titled "Effect of Donepezil on Speech Recognition in Cochlear Implant Users". Hearing loss is a major cause of disability that affects over 48 million Americans. There are currently no medications used to treat sensorineural hearing loss. Cochlear implants can significantly restore hearing in adults with moderate to profound sensorineural hearing loss, but their utility is li...
What is the current status of trial NCT05438264?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2023-03-10. Estimated completion is 2026-09-01.
What conditions does trial NCT05438264 study?
This clinical trial studies the following conditions: Bilateral Sensorineural Hearing Loss.
What interventions are being tested in trial NCT05438264?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG).
Who is sponsoring clinical trial NCT05438264?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05438264 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bilateral Sensorineural Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.